Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis
2025 · Journal of Lipid Research · 2 citations
https://doi.org/10.1016/j.jlr.2025.100753
J
José A. Inia
Netherlands Organisation for Applied Scientific Research(NL)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
28
Papers
99
Citations
4
h-index
4
i10-index
José A. Inia is an academic researcher from Netherlands Organisation for Applied Scientific Research. The author has contributed to research in topics: Lipoproteins and Cardiovascular Health & Liver Disease Diagnosis and Treatment & Cancer, Lipids, and Metabolism. The author has an h-index of 4, co-authored 24 publications.
ORCID: 0000-0002-3725-6785Papers by this author
worksA novel cardiovascular-kidney-metabolic syndrome mouse model with inducible HFrEF and atherosclerosis
2024 · Atherosclerosis · 0 citations
https://doi.org/10.1016/j.atherosclerosis.2024.118500
† Obicetrapib reduces atherosclerosis and vascular inflammation, mainly by reducing non-HDL-C, improves lesion stability adding to the beneficial effect of ezetimibe
2025 · Journal of clinical lipidology · 0 citations
https://doi.org/10.1016/j.jacl.2025.04.159
† Obicetrapib alone and in combination with ezetimibe increases reverse cholesterol transport and does not affect VLDL production
2025 · Journal of clinical lipidology · 0 citations
https://doi.org/10.1016/j.jacl.2025.04.161
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat